Skip to main content
Premium Trial:

Request an Annual Quote

CDI Labs HuScan and VirScan

CDI Laboratories' Antygen Division, which provides contract research for R&D in the therapeutic and diagnostic space, has launched two biomarker discovery assays, HuScan and VirScan. HuScan detects antibodies against the entire human proteome via long peptides on the surface of bacteriophages, antibody pulldown, and sequencing readouts. VirScan detect antibodies against the proteomes of every viral strain known to infect humans in the same manner. Both assays represent the first commercial use of PhIP-seq technology, the company said.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.